Stock Graphs and Charts

This is a complete list of financial data submitted by Ra Pharmaceuticals, Inc. to the Securities and Exchange Commission (SEC) in their recent 10K and 10Q filings. These terms are taken from the XBRL portion of the filings.

Click on a term to see historical data and generate a time series chart from the historical filings.

Term
Accounts Payable Current
Accounts Receivable Net
Accounts Receivable Net Current
Accretion Of Debt Issuance Costs And Discounts
Accrued Consulting Costs Current
Accrued Liabilities Current
Accrued Professional Fees Current
Accrued Research And Development Costs Current
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Additional Paid In Capital
Adjustments To Additional Paid In Capital Disgorgement Of Stockholder S Short Swing Profits
Adjustments To Additional Paid In Capital Other
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Adjustments To Additional Paid In Capital Warrant Issued
Allocated Share Based Compensation Expense
Amortization Of Intangible Assets
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Change In Fair Value Of Preferred Stock Tranche Rights
Class Of Warrant Or Rights Exercise Of Common Stock Warrants
Common Shares Outstanding
Common Stock Capital Shares Reserved For Future Issuance
Common Stock Number Of Votes Entitled Per Share
Common Stock Par Or Stated Value Per Share
Common Stock Shares Authorized
Common Stock Shares Issued
Common Stock Shares Outstanding
Common Stock Value
Conversion Of Stock Amount Converted1
Costs And Expenses
Current Federal Tax Expense Benefit
Current Foreign Tax Expense Benefit
Current State And Local Tax Expense Benefit
Deferred Federal Income Tax Expense Benefit
Deferred Foreign Income Tax Expense Benefit
Deferred Income Tax Liabilities
Deferred Income Tax Liabilities Net
Deferred Rent Credit Current
Deferred Rent Credit Noncurrent
Deferred Revenue Current
Deferred Revenue Noncurrent
Deferred State And Local Income Tax Expense Benefit
Deferred Tax Assets Accrued Expense And Other
Deferred Tax Assets Accrued Expenses
Deferred Tax Assets Capitalized RD Costs
Deferred Tax Assets Deferred Income
Deferred Tax Assets Gross
Deferred Tax Assets Intangible Assets And Amortization
Deferred Tax Assets License Payments Book Expense
Deferred Tax Assets Operating Loss Carryforwards Domestic
Deferred Tax Assets Operating Loss Carryforwards Foreign
Deferred Tax Assets Other
Deferred Tax Assets Tax Credit Carryforwards Research
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
Deferred Tax Assets Valuation Allowance
Deferred Tax Liabilities
Deferred Tax Liabilities Depreciation
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
Defined Contribution Plan Cost Recognized
Defined Contribution Plan Employer Matching Contribution Percent
Defined Contribution Plan Employer Matching Contribution Percent Of Match
Depreciation
Depreciation Depletion And Amortization
Dividends Common Stock
Earnings Per Share Basic And Diluted
Effective Income Tax Rate Continuing Operations
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
Employee Related Liabilities Current
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Extinguishment Of Stock Amount Converted
Extinguishment Of Temporary Equity
Fair Value Assets Amount Transferred Between Measurement Levels
Fair Value Assets Liabilities Transfers Between Levels Amount
Fair Value Liabilities Amount Transferred Between Measurement Levels
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
Finite Lived Intangible Assets Amortization Expense Total
Finite Lived Intangible Assets Amortization Expense Year Four
Finite Lived Intangible Assets Amortization Expense Year Three
Finite Lived Intangible Assets Amortization Expense Year Two
Gain Loss On Change In Fair Value Of Derivative Liability
Gains Losses On Extinguishment Of Debt
General And Administrative Expense
Goodwill
Goodwill Impairment Loss
Impairment Of Intangible Assets Excluding Goodwill
Income Loss From Continuing Operations Before Income Taxes Domestic
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
Income Loss From Continuing Operations Before Income Taxes Foreign
Income Tax Expense Benefit
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
Income Tax Reconciliation Foreign Income Tax Rate Differential
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
Income Tax Reconciliation Nondeductible Expense
Income Tax Reconciliation Other Adjustments
Income Tax Reconciliation State And Local Income Taxes
Income Tax Reconciliation Tax Credits
Increase Decrease In Accounts Payable And Accrued Liabilities
Increase Decrease In Capital Expenditures Incurred But Not Yet Paid
Increase Decrease In Deferred Rent
Increase Decrease In Deferred Rent And Other Noncurrent Liabilities
Increase Decrease In Deferred Revenue
Increase Decrease In Other Noncurrent Assets
Increase Decrease In Other Operating Capital Net
Increase Decrease In Prepaid Deferred Expense And Other Assets
Increase Decrease In Prepaid Deferred Expense And Other Current Assets
Increase Decrease In Prepaid Expense And Other Current Assets
Increase Decrease In Restricted Cash
Intangible Assets Net Excluding Goodwill
Interest Expense Related Party
Interest Income Operating
Lease And Rental Expense
Liabilities
Liabilities And Stockholders Equity
Liabilities Current
Net Cash Provided By Used In Continuing Operations
Net Cash Provided By Used In Financing Activities
Net Cash Provided By Used In Financing Activities Continuing Operations
Net Cash Provided By Used In Investing Activities
Net Cash Provided By Used In Investing Activities Continuing Operations
Net Cash Provided By Used In Operating Activities
Net Cash Provided By Used In Operating Activities Continuing Operations
Net Income Loss
Net Income Loss Available To Common Stockholders Basic
Nonoperating Income Expense
Number Of Operating Segments
Number Of Reporting Units
Operating Expenses
Operating Income Loss
Operating Leases Future Minimum Payments Due
Operating Leases Future Minimum Payments Due Current
Operating Leases Future Minimum Payments Due In Five Years
Operating Leases Future Minimum Payments Due In Four Years
Operating Leases Future Minimum Payments Due In Three Years
Operating Leases Future Minimum Payments Due In Two Years
Operating Leases Future Minimum Payments Due Thereafter
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
Other Accrued Liabilities Current
Other Asset Impairment Charges
Other Assets Noncurrent
Other Noncash Expense
Other Noncash Income Expense
Other Nonoperating Income Expense
Paid In Kind Interest
Payment Of Common Stock Offering Costs
Payments For Proceeds From Other Investing Activities
Payments For Proceeds From Tenant Allowance
Payments Of Debt Issuance Costs
Payments Of Preferred Stock Issuance Costs
Payments Of Stock Issuance Costs
Payments To Acquire Property Plant And Equipment
Preferred Stock Par Or Stated Value Per Share
Preferred Stock Redemption Discount
Preferred Stock Shares Authorized
Preferred Stock Shares Issued
Preferred Stock Shares Outstanding
Preferred Stock Tranche Rights
Prepaid Expense And Other Assets Current
Proceeds From Convertible Debt
Proceeds From Disgorgement Of Stockholders Short Swing Profits
Proceeds From Issuance Initial Public Offering
Proceeds From Issuance Of Convertible Preferred Stock
Proceeds From Offering
Proceeds From Payments For Other Financing Activities
Proceeds From Sale Of Property Plant And Equipment
Proceeds From Stock Options Exercised
Proceeds From Warrant Exercises
Profit Loss
Property Plant And Equipment Gross
Property Plant And Equipment Net
Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
Research And Development Expense
Restricted Cash And Cash Equivalents
Restricted Cash And Cash Equivalents Noncurrent
Retained Earnings Accumulated Deficit
Revenues
Share Based Compensation
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Shares Float
Stockholders Equity
Stockholders Equity Note Stock Split Conversion Ratio1
Stock Issuance Costs Incurred But Not Yet Paid
Stock Issued During Period Value Conversion Of Convertible Securities
Stock Issued During Period Value New Issues
Stock Issued During Period Value Stock Options Exercised
Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense
Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit
Temporary Equity Preferred Stock Tranche Rights Gain Loss On Fair Value Adjustment
Unrecognized Tax Benefits
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
Valuation Allowance Deferred Tax Asset Change In Amount
Weighted Average Number Of Share Outstanding Basic And Diluted

Peers -

Related News Stories

Recent IPO Replimune: Oncolytic Viral Technology

2018-08-28 seekingalpha
Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M. (30-0)

Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?

2018-07-30 seekingalpha
Ra Pharma is developing RA101495, a C5 inhibitor and a potential competitor to Alexion's blockbuster Soliris. (7-0)

Insiders Are Bullish On Tiny Tonix (Again)

2018-07-24 seekingalpha
TNXP remains appropriate only for investors who can stomach the high risk in this potentially high-reward punt. (7-5)

Riding Ra Pharmaceuticals

2018-07-23 seekingalpha
Shares of Ra Pharmaceuticals (NASDAQ:RARX) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. (8-0)

6 Speculative BioHealth Analyst Stocks That Could Rally 50% to 300%

2018-07-21 247wallst
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside. (55-17)

Top Analyst Upgrades and Downgrades: AEP, Facebook, Microsoft, PayPal, Philip Morris, Spotify, Under Armour and More

2018-07-20 247wallst
Stocks were indicated lower on Friday on more China woes, but it’s been a choppy time of late. The investing community has had less faith and has seen lower rewards from buying the dips in 2018 than in prior years. Many of those same investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and into 2019 and beyond. (49-2)

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

2018-05-31 seekingalpha
This article is the second of two parts discussing Alexion Pharmaceuticals (ALXN) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXN’s competition. I have previously reviewed a large number of ALXN’s competitors back in October, 2017, but there have been some important developments since worth reviewing. Further, given the recent phase 3 success of ALXN1210 in paroxysmal nocturnal hemoglobinuria (PNH), and with results in atypical hemolytic uremic syndrome (aHUS) coming in Q4’18, it now becomes prudent to compare the competitors' drugs to ALXN1210, not just Soliris. (146-2)

5 Clinical-Stage Biotech Stocks to Buy Under $10

2018-05-29 investorplace
Not many sectors offer the potential for big time gains like biotech. Especially when you’re looking at smaller clinical-stage names. After all, the thrill of getting a big-time approval or even making through to the next round of FDA trail phases can send a biotech stock’s price surging. Conversely, one mishap can send shares crashing. (220-5)

ChemoCentryx: Discounted, Underfollowed, And Misunderstood Biotech

2018-05-07 seekingalpha
After getting my toes wet in the renal-disease space with my previous overview article, I came across two companies I really like: Achillion (ACHN) and ChemoCentryx (CCXI). Ra Pharmaceuticals (RARX) and Omeros (OMER) are both contenders with potentially great upside as well, and should be followed closely. (27-2)

Alexion Clears A Path For 2nd Generation PNH Drug

2018-04-30 seekingalpha
Alexion obtains positive phase 3 results for SWITCH study in treating patients with rare blood disease. (58-0)

CUSIP: 74933V108